Evidence map›Paper›PMID 36672704›Full record

ArticleBiomedicines2023

Esterification of

Joana I Carmo-Martins, Michelangelo B Gonzatti, Marina T Varela, Maria Eduarda P Sousa, Lucas V S Costa, Elaine Guadelupe Rodrigues, João Paulo S Fernandes, Alexandre C Keller

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Ferulic andRSC advances · 2026
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Joana I Carmo-MartinsDepartment of Microbiology, Immunology, and Parasitology, Division of Immunology, Escola Paulista de Medicina, Universidade Federal de São Paulo, campus São Paulo, São Paulo 04023-062, Brazil.
Michelangelo B GonzattiDepartment of Microbiology, Immunology, and Parasitology, Division of Immunology, Escola Paulista de Medicina, Universidade Federal de São Paulo, campus São Paulo, São Paulo 04023-062, Brazil.
Marina T VarelaDepartment of Pharmaceutical Sciences, Institute of Environmental, Chemical and Pharmaceutical Sciences, Universidade Federal de São Paulo, campus Diadema, Diadema 09913-030, Brazil.ORCID 0000-0003-2152-9758
Maria Eduarda P SousaDepartment of Microbiology, Immunology, and Parasitology, Division of Immunology, Escola Paulista de Medicina, Universidade Federal de São Paulo, campus São Paulo, São Paulo 04023-062, Brazil.
Lucas V S CostaDepartment of Microbiology, Immunology, and Parasitology, Division of Immunology, Escola Paulista de Medicina, Universidade Federal de São Paulo, campus São Paulo, São Paulo 04023-062, Brazil.
Elaine Guadelupe RodriguesDepartment of Microbiology, Immunology, and Parasitology, Division of Cell Biology, Escola Paulista de Medicina, Universidade Federal de São Paulo, campus São Paulo, São Paulo 04023-062, Brazil.ORCID 0000-0002-3248-3081
João Paulo S FernandesDepartment of Pharmaceutical Sciences, Institute of Environmental, Chemical and Pharmaceutical Sciences, Universidade Federal de São Paulo, campus Diadema, Diadema 09913-030, Brazil.ORCID 0000-0002-9089-273X
Alexandre C KellerDepartment of Microbiology, Immunology, and Parasitology, Division of Immunology, Escola Paulista de Medicina, Universidade Federal de São Paulo, campus São Paulo, São Paulo 04023-062, Brazil.
Universidade Federal de São Paulo · BR

Funding

CNPq 308964/2019-5 and 306355/2018-3Coordenação de Aperfeicoamento de Pessoal de Nível Superior Finance code 001São Paulo Research Foundation (FAPESP) 2019/11490-5 2019/24028-8 2018/03918-2 2021/11200-7
6 · The paper itself

Abstract

Previous studies reported that p-coumaric acid modulates melanoma growth. Because the esterification of p-coumaric acid (p-CA) enhanced its activity as an antimelanogenic agent, we aimed to determine the antitumor potential of two derivatives, the ethyl and butyl esters, against the murine B16-F10 and the human SK-MEL-25 melanoma cells. Cell viability was determined in vitro by the lactate dehydrogenase release and violet crystal absorption assays. The cell proliferation rate and cell cycle behavior were determined by the colony formation assay and flow cytometry analysis. Although p-CA, at the concentration of 1 mM, failed to exert a significant antitumor activity, the ethyl and butyl ester derivatives caused substantial tumor cell death at doses < 1 mM. Despite a reduction in their direct cytotoxicity at minor doses, both products controlled the melanoma growth by arresting the cell cycle at the G0/G1 (B16-F10) or S/G2 (SK-MEL-25). Furthermore, the in vivo experiments showed that the butyl ester derivative suppressed the lung B16-F10 burden, compared to the p-CA-treated mice. Thus, the esterification of p-coumaric acid improved the control over the proliferation of murine and human melanoma cells and can be considered an approach for designing novel anticancer agents.

Indexed as

B16-F10cell growthmelanomap-coumaric acidtumor

Identifiers

PMID36672704
PMCPMC9855326
OpenAlexW4315780884

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.